Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027674 | 0.80 | MAPT (0.47) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL18701715 | 0.78 | DAO (0.42) | MAPTTSHRKMT2AALDH1A1KDM4E | |
| SCHEMBL14670271 | 0.77 | MAPT (0.44) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL12272115 | 0.77 | MAPT (0.57) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL26281532 | 0.77 | KMT2A (0.44) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL2730725 | 0.77 | MAPT (0.44) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL381164 | 0.77 | MAPK14 (0.52) | MAPTTSHRKMT2AHSD17B10IKBKB | |
| SCHEMBL13545971 | 0.77 | MAPT (0.44) | MAPTTSHRKMT2AHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5445499 | 0.76 | MAPK14 (0.51) | MAPTTSHRKMT2AHSD17B10IKBKB | |
| SCHEMBL13994843 | 0.76 | ALOX15 (0.44) | MAPTTSHRKMT2AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2020046975-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019136025-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | MAPT 2/4885TSHR 3759/4885KMT2A 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.